Inactive Instrument

Press Releases Ayala Pharmaceuticals, Inc.

Stocks

ADXS

US0076244062

Biotechnology & Medical Research

Press Releases

24-05-09	Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations	AQ
24-03-26	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	AQ
24-02-20	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	AQ
24-02-06	Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	AQ
23-11-06	Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors	AQ
23-10-23	Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	AQ
23-10-19	Ayala Pharmaceuticals Announces Closing of Merger with Biosight	AQ
23-08-10	Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update	AQ
23-08-01	Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023	AQ
23-07-27	Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement	AQ
23-07-05	Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors	AQ
23-06-05	Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
23-05-25	Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
23-05-23	Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update	AQ
23-04-27	Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
23-04-07	AYALA PHARMACEUTICALS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
23-04-06	AYALA PHARMACEUTICALS, INC. Financial Statements and Exhibits (form 8-K/A)	AQ
23-03-03	Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee	GL
23-02-10	Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022	GL
23-02-10	AYALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
23-01-30	Advaxis : Certificate of Incorporation/Bylaws - Form 8-K	PU
23-01-30	AYALA PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	AQ
23-01-25	AYALA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
23-01-13	ADVAXIS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure (form 8-K)	AQ
23-01-12	ADVAXIS, INC. : Other Events (form 8-K)	AQ